Isolated Case of Marburg Virus Disease, Kampala, Uganda, 2014


In September 2014, a single fatal case of Marburg virus was identified in a healthcare worker in Kampala, Uganda. The source of infection was not identified, and no secondary cases were identified. We describe the rapid identification, laboratory diagnosis, and case investigation of the third Marburg virus outbreak in Uganda.

Marburg virus disease (MVD) is caused by Marburg virus (MARV; family Filoviridae, which also includes Ebola viruses). The disease was first discovered in 1967 in Marburg and Frankfurt, Germany, after laboratory workers were infected from monkeys imported from Uganda (7). Thereafter, sporadic cases and outbreaks of MVD have been documented in South Africa, Kenya, the Democratic Republic of the Congo, Angola, Uganda, the Netherlands, and the United States (2). MVD remains of great public health importance because of the case-fatality rate, which can be as high as 90%, and documented human-to-human transmission, with associated socioeconomic consequences.

Uganda has experienced previous outbreaks of MVD, resulting in fatalities and socioeconomic effects from loss of tourism. The first recorded outbreak in Uganda occurred in the Kamwenge district in 2007, where 4 MVD cases were confirmed in miners at the Kitaka mine (3). A second, larger outbreak occurred in the western Uganda districts of Kabale, Ibanda, and Kamwenge in 2012 (4). In addition, tourists from the United States and the Netherlands were infected with MARV in western Uganda when they visited Python Cave in Queen Elizabeth National Park in 2008 (5,6). Both Python Cave and the Kitaka mine are inhabited by Egyptian fruit bats (Rousettus aegyptiacus), the host reservoir of MARV (7).

In 2014, a fatal case of MVD occurred in Uganda. We report here on the field and laboratory investigation of this case, including possible sources of infection.

The Study

On September 23, 2014, a healthcare worker was admitted to Mengo Hospital in Kampala, Uganda, with a febrile illness suspected to be viral hemorrhagic fever (VHF) infection. The patient, a 30-year-old man, was a radiographer who worked at Mengo Hospital and part-time at Mpigi Health Center IV in the Mpigi district, ≈30 km south of Kampala (Figure 1). His symptoms began on September 17, 2014. A rapid diagnostic test result was positive for malaria, and the patient was given intravenous ceftriaxone, 5% dextrose, and artesunate. However, his condition continued to deteriorate.

On September 26, he began to display hemorrhagic signs, notably profuse bleeding from body orifices. Clinical findings included fever (temperature 38.4°C), nausea, vomiting, diarrhea, musculoskeletal pain, abdominal pain, headache, sore throat, difficulty swallowing, difficulty breathing, anorexia, bleeding from the nose, bloody stools, vomiting blood, and upper gastrointestinal tract bleeding. He died on September 28.

Whole blood and serum samples collected on September 28 were sent to the Uganda Virus Research Institute (UVRI)/US Centers for Disease Control and Prevention (CDC) VHF laboratory in Entebbe for testing on September 30. We performed diagnostic testing by real-time reverse transcription PCR (RT-PCR), antigen detection, and MARV IgM ELISA on the suspected sample as described (8). We detected MARV by RT-PCR, but antigen detection and IgM serologic results were negative.

We obtained independent confirmation from duplicate whole blood and serum samples by using RT-PCR primers and probes targeting MARV VP40 gene and a commercial filovirus PCR screening assay (Altona Diagnostics, Hamburg, Germany) (9) (Table). On the basis of the positive RT-PCR results, we confirmed MVD in this patient. We shipped specimens to the CDC Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases (Atlanta, GA, USA), for further testing, including virus isolation and sequencing. A virus isolate

Author affiliations: Uganda Virus Research Institute, Entebbe, Uganda (L. Nyakarahuka, J. Lutwama); US Centers for Disease Control and Prevention, Entebbe (J. Ojwang, A. Tumusiime, S. Balinandi, J. Borchert, T.R. Shoemaker); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S. Whitmer, U. Ströher, P.E. Rollin, S.T. Nichol); Public Health Emergency Operations Center, Kampala, Uganda (S. Kyazze, S. Kasozi, M. Wetaka, I. Makumbi, M. Dahlke)

DOI: https://dx.doi.org/10.3201/eid2306.170047
(812601) was generated from the clinical specimen after a single passage in cell culture (Vero E6).

After laboratory confirmation, a multidisciplinary team from UVRI and CDC-Uganda performed the initial outbreak investigations at Mengo Hospital and Mpiigi Health Center IV. The investigation team provided the outbreak case definition, and details of case contacts were obtained from both health facilities. An investigation was also performed in Kasese District, where the health worker was taken for burial. In addition, an ecologic investigation was conducted to identify roosting sites nearby for the potential presence of R. aegyptiacus bats. We created an outbreak database using the Epi Info Viral Hemorrhagic Fever outbreak management application (10). All case and contact data were managed by the Uganda Ministry of Health Public Health Emergency Operations Center. We identified 197 close contacts, who were followed for 21 days. During the course of follow-up, 33 (16.2%) of the 197 contacts converted to suspected case-patients by exhibiting clinically compatible signs or symptoms matching the outbreak case definition. Blood samples from suspected case-patients were tested at the UVRI/CDC laboratory in Entebbe; all were negative for MARV by RT-PCR and serologic analysis.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 6, June 2017

Marburg Virus Disease, Kampala, Uganda

Conclusions

We describe the second single-case filovirus outbreak detected in Uganda; a case of infection with *Sudan ebolavirus* was reported in Luwero District in 2011 (11). The investigation was unable to identify a conclusive source of infection, including evidence of the natural reservoir host near where the infected patient was working or residing or potential cases in persons who visited health centers before this case was confirmed. No secondary cases arose from contact with the initial case-patient.

The patient tested positive for malaria but later tested positive for MARV by RT-PCR and serologic analysis. These findings indicate that co-infection of viral hemorrhagic fever (VHF) and other tropical infectious diseases can confound diagnosis and delay early detection, potentially resulting in large outbreaks that are much harder to control, as was seen during the 2014–2015 Ebola virus outbreak in West Africa (12). This finding emphasizes the need for continued surveillance and awareness even when other, more common pathogens are initially suspected.

The finding of no secondary cases in this investigation can be attributed, in part, to use of infection control practices and personal protective equipment when first encountering a suspected VHF case. Because Uganda has experienced 10 VHF outbreaks since 2011, increased awareness and use of personal protective equipment and infection control practices have greatly limited secondary transmission, especially in the healthcare setting. Routine use of gloves, protective gowns, and chlorine is now more common in lower-level healthcare facilities in Uganda.

<table>
<thead>
<tr>
<th>Genome fragment</th>
<th>Primer set</th>
<th>Primer sequence, 5′→3′</th>
<th>Region amplified</th>
<th>Region size, kbp</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>63F</td>
<td>TGA CAT TGA GAC TTG TCA GTC</td>
<td>64-4998</td>
<td>4.9</td>
</tr>
<tr>
<td></td>
<td>MARB-4997R</td>
<td>GCT TGA TTT CCT TCA CGC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>3005F</td>
<td>AAG TCA GGG AGG GGT TGA TGA CTG GAA AAG TGC TAT GGT CCC TTC AGT GAA GAC</td>
<td>2970-6438</td>
<td>3.5</td>
</tr>
<tr>
<td></td>
<td>6426R</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>6101F</td>
<td>AGA AAA CAG AAG ACG TCC ATC TGA TG</td>
<td>6065-9405</td>
<td>3.3</td>
</tr>
<tr>
<td></td>
<td>9405R</td>
<td>ACT TAA TGC TGC ACG AAG TGA TG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>7567F</td>
<td>TGG CCC TGG AAT IGA AAG ACT C</td>
<td>7548-10571</td>
<td>3.0</td>
</tr>
<tr>
<td></td>
<td>10571R</td>
<td>AGC ATA TGA ACA ATA GAT C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>36F</td>
<td>GTA CCT CTA AGG AAA ATC ATG AAG GTC GAT AT A AT ATT GCA GCT GTA GAT</td>
<td>9979-15442</td>
<td>5.4</td>
</tr>
<tr>
<td></td>
<td>57R</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>12006F</td>
<td>TTG CCA GAA GGA TAA AAG GAC AAA GAG ATT TGA GAT TAT ATT ATC ACT TAC</td>
<td>11953-15486</td>
<td>3.5</td>
</tr>
<tr>
<td></td>
<td>15516R</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>15519F</td>
<td>TGG ACA ATG GAA AAA AAT CGA GCA C</td>
<td>15108-19111</td>
<td>4.0</td>
</tr>
<tr>
<td></td>
<td>19155R</td>
<td>TGG ACA CAC TAA AAA GAT G</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table. Primers used to generate Marburg virus-specific cDNA fragments for whole-genome sequencing of isolates from Uganda

Figure 2. Phylogenetic tree comparing complete or nearly complete Marburg virus (MARV) genomes sequenced from bat and human sources in Uganda. A consensus whole-genome sequence was assembled by mapping reads to the reference MARV sequence NC_001608 using CLC Genomics Workbench (Waltham, MA, USA). A phylogenetic tree was constructed using MEGA6.06 (http://www.megasoftware.net). Viral sequences acquired from human sources are in standard type, and viral sequences acquired from bats are italicized; the sequence from the human case-patient described in this study, MBG 812601 2014, is in bold. Evolutionary history was inferred using the maximum-likelihood method based on the Tamura-Nei model with MEGA6.06. The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. Values at nodes represent bootstrap values following 1,000 replicates. Scale bar represents substitutions per site. GenBank accession numbers used in this tree are KP985768, JX458855.1, FJ750957.1, JX458852.1, JX458854.1, FJ750958.1, JX458856.1, JX458828.1, JX458826.1, JX458834.1, DQ447651.1, JX458846.1, AY358025.2, DQ447657.1, Z12132.1, NC_001608.3, 229337.1, EF446132.1, JN408064.1, KC545388.1, KC545387.1, DQ447649.1, EF446131.1, DQ447652.1, FJ750956.1, FJ750955.1, and FJ750953.1.
protective products were used at both Mengo Hospital and Mpigi Health Center IV.

The full genomic sequence of this MARV isolate (812601; Genbank accession no. KP985768) falls into a cluster that consists mostly of MARV sequences isolated from bats. The closest related sequence was obtained from MARV isolated from a juvenile male R. aegyptiacus bat (Q843) captured in August 2009 in Python Cave, Queen Elizabeth National Park (Figure 2). Other viral sequences from bat specimens in this clade were from bats collected from either Python Cave or the Kitaka mine during 2007–2009. The most closely related human sequence (01Uga07) was from a miner who worked in the Kitaka mine in July 2007 (3, 7). Because of the wide genetic diversity of MARVs, there is no definitive way to identify where this patient may have become infected.

We do not know why the patient did not transmit MARV to any of his close contacts. We can assume that none of the contacts had substantial exposure to the patient while he was infectious. The relatively small size of this and previous filovirus outbreaks in Uganda can be attributed to enhanced VHF surveillance, rapid case identification, laboratory testing, and investments from the global health security agenda in rapid sample transportation to the national VHF reference laboratory for diagnostic testing (13). VHF surveillance continues to be a top priority for Uganda, and the VHF surveillance program continues to play a crucial role in detecting, responding to, and helping to control these outbreaks.

Acknowledgments
We thank the staff at Mengo Hospital, Kampala, and Mpigi Health Center IV; the initial investigation team, which included members from UVRI and CDC-Uganda for field and laboratory investigation of the outbreak; the Ministry of Health National Task Force on Epidemic Preparedness and Response; World Health Organization; Kampala City Council Authority; Kasese and Mpigi local governments; CDC Uganda, CDC, and UVRI Motorpool for transportation; and Médecins Sans Frontières for establishing an isolation ward at Mulago Hospital. We especially thank UVRI for its support of the VHF surveillance program and diagnostics laboratory. We also thank the United States Agency for International Development, African Field Epidemiology Network, and the United Nations Children’s Fund, which all participated and contributed to the Marburg outbreak response and provided support to the Uganda Ministry of Health.

Dr. Nyakarahuka is a zoonotic disease epidemiologist at the Uganda Virus Research Institute in Entebbe, Uganda, with a background in veterinary medicine and public health. His work specifically focuses on the surveillance, detection and investigation of viral hemorrhagic fevers, including Ebola and Marburg viruses, and he specializes in characterizing the natural ecology of hemorrhagic fever viruses.

References

Address for correspondence: Trevor R. Shoemaker, Centers for Disease Control and Prevention, P.O. Box 7007, Plot 1577 Ggaba Road, Kampala, Uganda; email: tis8@cdc.gov